Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2–3, non-randomised study

Authors

Elisabeth Baudin (ORCID: https://orcid.org/0000-0002-6575-6971)
Jorge Seixas (ORCID: https://orcid.org/0000-0002-3110-6583)
Christelle Perdrieu
Enock Matovu (ORCID: https://orcid.org/0000-0003-0714-7032)
Marshal Lemerani
Bruno Scherrer (ORCID: https://orcid.org/0000-0001-6097-4489)
Veerle Lejon (ORCID: https://orcid.org/0000-0002-6795-0962)
Aita Signorell (ORCID: https://orcid.org/0000-0003-3890-3910)
Charles Wamboga
Olaf Valverde Mordt (ORCID: https://orcid.org/0000-0002-3898-1014)
Anne Reymondier
Westain Nyirenda
Anthony Eriatu
Deolinda Alves

Institutions

Centre de Coopération Internationale en Recherche Agronomique pour le Développement (FR)
Swiss Tropical and Public Health Institute (CH)
University of Basel (CH)
Ministry of Health (UG)
Ministry of Health (MW)
Services déconcentrés d'appui à la recherche Occitanie-Montpellier (FR)
Institut de Recherche pour le Développement (FR)
Makerere University (UG)
Universidade Nova de Lisboa (PT)

Publication Details

Journal: The Lancet Global Health
Published: 2025-04-24
DOI: https://doi.org/10.1016/s2214-109x(25)00016-6
Citations: 6
Primary Topic: Trypanosoma species research and implications
Type: article
Field-Weighted Citation Impact: 8.13

Funders

Médecins Sans Frontières
Department for International Development
Direktion für Entwicklung und Zusammenarbeit
European and Developing Countries Clinical Trials Partnership

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2–3, non-randomised study

Elisabeth Baudin, Jorge Seixas, Christelle Perdrieu, Enock Matovu et al.

Apr 24, 2025

6 citations

The Lancet Global Health

Trypanosoma species research and implications

8.13

article

Fexinidazole as a new oral treatment for human African trypanosomiasis due to Trypanosoma brucei rhodesiense: a prospective, open-label, single-arm, phase 2–3, non-randomised study

Elisabeth Baudin, Jorge Seixas, Christelle Perdrieu, Enock Matovu, Marshal Lemerani, Bruno Scherrer, Veerle Lejon, Aita Signorell, Charles Wamboga, Olaf Valverde Mordt, Anne Reymondier, Westain Nyirenda, Anthony Eriatu, Deolinda Alves

April 24, 2025article en

6 citations

Abstract

No abstract available for this paper.

The Lancet Global HealthVol. 13(5)

Centre de Coopération Internationale en Recherche Agronomique pour le Développement (FR), Swiss Tropical and Public Health Institute (CH), University of Basel (CH), Ministry of Health (UG), Ministry of Health (MW), Services déconcentrés d'appui à la recherche Occitanie-Montpellier (FR), Institut de Recherche pour le Développement (FR), Makerere University (UG), Universidade Nova de Lisboa (PT)

Médecins Sans Frontières, Department for International Development, Direktion für Entwicklung und Zusammenarbeit, European and Developing Countries Clinical Trials Partnership

Good health and well-being

Openalex Percentile: Top 2%

Trypanosoma species research and implications

8.13

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.